Project Grant HT94252510746
Award Date
9/1/25
Completion Date
8/31/29
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23284, USA
Similar Awards
This federal Project Grant award in the amount of $582,189.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Virginia Commonwealth University (VCU) to investigate the role of histone H2A ubiquitination and the RSF1 gene in breast cancer. The 3-year award, starting on March 1, 2024, will fund personnel, facilities, and equipment to conduct basic, translational, and clinical research aimed at advancing...
The Department of Defense's Defense Health Agency awarded a $1,836,611 Project Grant to Virginia Commonwealth University (VCU) under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports advanced biomedical research to develop a novel cell therapy for the treatment of advanced prostate cancer. VCU, a public research university in Richmond, Virginia, has demonstrated extensive capabilities in scientific research and technical...
The Department of Defense's Defense Health Agency awarded Virginia Commonwealth University (VCU) a $568,461 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "READING HISTONE H2A UBIQUITINATION IN THE FUNCTION OF RSF1 IN BREAST CANCERS WITH RSF1 GENE AMPLIFICATION." The grant, effective from March 1, 2024 through February 28, 2027, will fund VCU's research to advance the scientific understanding of breast cancer and develop...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $961,900.00 to Virginia Commonwealth University (VCU) for the Early Detection of Cancer Disparity and Treatment Resistance in TNBC project. The 3-year award, effective February 1, 2024, supports research to advance early detection and treatment of triple-negative breast cancer (TNBC), which disproportionately impacts minority populations. The funding will enable...
The federal Project Grant award of $5,471,258.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to The University of Texas M.D. Anderson Cancer Center supports research aimed at "Targeting Ganglioside GD2 to Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer". This 4-year grant, awarded on September 1, 2025, will fund advanced biomedical research to transform healthcare for military service members, veterans, and the public by...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
This federal Project Grant award of $2,542,500.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research aimed at therapeutically targeting the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse, as well as preclinical models of lung metastases. The award was granted to the Weill Medical College of Cornell University, a prestigious academic medical institution, with a performance...
The Virginia Commonwealth University will receive $1.5 million over four years from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to manage distress in malignant brain cancer. Through this Project Grant award issued on August 1, 2021 and concluding on July 31, 2025, VCU will provide services to transform healthcare for service members and the public through innovative research investigating medical solutions for the...
The federal Project Grant award of $718,858.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award was granted to The University of Texas M.D. Anderson Cancer Center on February 15, 2025, with a planned completion date of February 14, 2028. As a leading academic cancer research institution, M.D....
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,552,466.00 to Virginia Commonwealth University to develop unique oncolytic adenoviruses for the pursuit of ovarian cancer cells. The award period runs from May 1, 2025 to April 30, 2029. The funding supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. This project-based grant focuses...